The optimal long-term treatment of venous thromboembolism

Affiliations

Review

Paolo Prandoni. Clin Adv Hematol Oncol. 2004 Nov.

. 2004 Nov;2(11):729-32.

¹ 2nd Chair of Internal Medical and Surgical Sciences, University of Padua, Italy. paoloprandini@tin.it

No abstract available

Similar articles

Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD, Pineo GF, Stein P. Hull RD, et al. Int Angiol. 1998 Dec;17(4):213-24. Int Angiol. 1998. PMID: 10204652 Review.
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F, Julian JA, Kearon C. Couturaud F, et al. Thromb Haemost. 2001 Oct;86(4):980-4. Thromb Haemost. 2001. PMID: 11686355
Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme.
Hull RD, Pineo GF. Hull RD, et al. Int Angiol. 1998 Sep;17(3):131-4. Int Angiol. 1998. PMID: 9821024 Review. No abstract available.
Low-molecular-weight heparin for initial treatment of venous thromboembolism.
Brewer D. Brewer D. Am Fam Physician. 2005 Jul 1;72(1):75-6. Am Fam Physician. 2005. PMID: 16035683 Review. No abstract available.
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F. Ferretti G, et al. J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250. doi: 10.1200/JCO.2005.01.7897. J Clin Oncol. 2005. PMID: 16192623 No abstract available.